5 near-term catalysts to consider: - Announcement of EU distribution deals / Upfront money - Results release of recent Vesele/Viagra study. Vesele sales will skyrocket IMO - New Product launches (plus new distribution channels)...still at least 4 to come in 2017 - June 19, 2017 is the Annual Shareholder meeting. Higher PPS = Higher Morale - FlutiCare FDA approval of ANDA (Novalere). A 2nd manufacturer ! Tweet Tweet ** Note - help yourself by NOT setting Stop Loss orders. Also, set Sell Stops in multiple dollars to "mark" your shares ! Low floater folks